Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma

Pyoderma gangrenosum (PG) is a rare, ulcerative neutrophilic dermatosis that has been reported in association with certain medications. Recognition of medications trigger PG may help to better understand the pathogenesis condition and provide earlier diagnosis treatment for affected patients. Herein, we report case new-onset following initiation checkpoint inhibitor pembrolizumab metastatic cutaneous squamous cell carcinoma. Our was resistant intralesional corticosteroid therapy, but ultimately improved systemic corticosteroids cessation pembrolizumab.